PGNX Progenics Pharmaceuticals Inc.

4.46
-0.16  -3%
Previous Close 4.62
Open 4.62
Price To Book 3.28
Market Cap 377059612
Shares 84,542,514
Volume 1,061,914
Short Ratio
Av. Daily Volume 1,288,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing of first patient announced December 3, 2018. Data due early 2020.
PyL
Prostate cancer
FDA approval announced July 30, 2018.
Azedra
Pheochromocytoma
Phase 3 trial met one of two co-primary endpoints.
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Approved July 19 2016.
Oral RELISTOR
Chronic pain
Approved September 29, 2014.
Subcutaneous RELISTOR
Chronic pain
Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.
PSMA ADC
Cancer - metastatic castrate resistant prostate cancer (mCRPC).
Phase 2 trial to be initiated 2Q 2019.
1095
Prostate Cancer

Latest News

  1. 3 Small Biotechs to Watch as Earnings Season Winds Down
  2. Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
  3. Market Trends Toward New Normal in Agilent Technologies, Xilinx, Interpublic Group of Companies, Progenics Pharmaceuticals, Flexsteel Industries, and USA Truck — Emerging Consolidated Expectations, Analyst Ratings
  4. Steven Cohen Storms Into Progenics Pharmaceuticals
  5. Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
  6. Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer 
  7. Here Are 3 Small-Cap Names for Biotech Investors to Consider
  8. What Did Progenics Pharmaceuticals, Inc.’s (NASDAQ:PGNX) CEO Take Home Last Year?
  9. Should You Buy NanoString Technologies Inc (NSTG)?
  10. Is Noodles & Co (NDLS) A Good Stock To Buy?
  11. Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer
  12. Research Report Identifies Capstone Turbine, LivePerson, Diamondback Energy, Presidio, Pretium Resources, and Progenics Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  13. Edited Transcript of PGNX earnings conference call or presentation 8-Nov-18 1:30pm GMT
  14. Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates
  15. Progenics: 3Q Earnings Snapshot
  16. Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8